Blog - COPE

COPE supported centers are pleased to provide a blog for patients and family members of patients that provides more information on ketamine treatments and mental illness.


Esketamine (Spravato): What You Need To Know About Breakthrough The Nasal Spray

There’s tons of excitement in psychiatry after the US Food and Drug Administration advisory committee recently backed esketamine (Spravato), an intranasal form of ketamine for treatment-resistant depression. This is an exciting and hopeful advancement because there hasn’t been a different pharmacologic depression treatment target approved by the agency in decades (Think: Prozac’s arrival in 1986). Like any new drug, the excitement and hope surrounding esketamine (Spravato) needs to be weighed by risks and benefits. Here are a few things you need to know about esketamine (Spravato).

5 Ways COPE Helps Smash Treatment-Resistant Depression in Atlanta

Imagine what it’s like to try medication after medication without experiencing relief. For one-third of people with major depression, this is their reality. Traditional antidepressants fall short. Symptoms linger and continue to weigh people down. It’s time to try something beyond the standard protocol and COPE Atlanta is the solution-here’s why…